Cubist Systematic Strategies, LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 221 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.

Quarter-by-quarter ownership
Cubist Systematic Strategies, LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$4,603,699
+4.2%
650,240
+3.6%
0.03%
+17.2%
Q2 2023$4,419,056
+17.1%
627,707
+38.7%
0.03%
+26.1%
Q1 2023$3,774,812
+24905.4%
452,615
+34319.4%
0.02%
Q4 2022$15,096
-99.4%
1,315
-99.3%
0.00%
-100.0%
Q3 2022$2,495,000
+501.2%
198,043
+404.9%
0.01%
+366.7%
Q2 2022$415,000
-83.2%
39,222
-74.2%
0.00%
-85.7%
Q1 2022$2,473,000
+1960.8%
152,074
+1648.2%
0.02%
+2000.0%
Q4 2021$120,000
-85.5%
8,699
-84.9%
0.00%
-90.0%
Q3 2021$829,000
-24.4%
57,658
-16.9%
0.01%
-16.7%
Q2 2021$1,096,000
+160.3%
69,354
+67.3%
0.01%
+140.0%
Q1 2021$421,000
-87.6%
41,444
-90.9%
0.01%
-89.4%
Q4 2020$3,401,000
+8402.5%
456,564
+3830.8%
0.05%
+4600.0%
Q3 2020$40,000
+1233.3%
11,615
+1559.3%
0.00%
Q2 2020$3,000
-92.3%
700
-96.4%
0.00%
-100.0%
Q1 2020$39,000
+333.3%
19,600
+653.8%
0.00%
Q4 2019$9,000
-91.2%
2,600
-90.4%
0.00%
-100.0%
Q2 2019$102,000
+13.3%
27,016
+143.6%
0.00%
-33.3%
Q1 2019$90,000
+12.5%
11,092
+11.6%
0.00%
-25.0%
Q4 2018$80,000
-41.6%
9,937
-44.5%
0.00%
-42.9%
Q3 2018$137,000
+69.1%
17,894
+26.0%
0.01%
+75.0%
Q2 2018$81,000
-31.4%
14,200
+1.3%
0.00%
-50.0%
Q1 2017$118,000
-12.6%
14,016
-70.7%
0.01%0.0%
Q1 2016$135,000
-76.4%
47,804
+24.8%
0.01%
-71.4%
Q2 2015$572,00038,2900.03%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Burrage Capital Management LLC 1,105,673$8,237,0006.28%
Sarissa Capital Management LP 8,175,000$60,903,0006.22%
ORACLE INVESTMENT MANAGEMENT INC 2,980,870$22,207,0002.78%
DG Capital Management, LLC 1,075,732$8,014,0001.70%
Ghost Tree Capital, LLC 900,000$6,705,0001.49%
Parkman Healthcare Partners LLC 538,370$4,011,0001.03%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 5,835,810$43,477,0000.86%
Formidable Asset Management, LLC 470,419$3,470,0000.80%
KNOTT DAVID M 219,461$1,635,0000.74%
Altium Capital Management LP 250,000$1,863,0000.70%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders